NTRX-07

DRUG3 trials

Sponsors

Neurotherapia Inc., NeuroTherapia, Inc.

Conditions

Alzheimer DiseaseMild Cognitive ImpairmentMild Cognitive Impairment (MCI)Mild to moderate Alzheimer’s Disease (AD)

Phase 1

A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07

CompletedNCT06194552

NeuroTherapia, Inc.Alzheimer Disease

Start: 2022-09-06End: 2023-06-30Updated: 2024-01-08

Phase 2

A Multicenter, Randomized, Double-masked, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) Effects of NTRX-07 in Subjects with Mild Cognitive Impairment (MCI) or Mild to Moderate Alzheimer’s Disease (AD) (SPPN-AD)

RecruitingCTIS2024-517957-29-00

Neurotherapia Inc.Mild Cognitive Impairment (MCI), Mild to moderate Alzheimer’s Disease (AD)

Start: 2025-04-02Target: 48Updated: 2025-08-04

A Study of NTRX-07 in Participants With Alzheimer's Disease

RecruitingNCT07058688

NeuroTherapia, Inc.Alzheimer Disease, Mild Cognitive Impairment

Start: 2025-03-01End: 2026-06-30Target: 48Updated: 2025-07-10